Coherus Oncology, Inc. (CHRS) vs Cue Biopharma, Inc. (CUE)
A side-by-side comparison of Coherus Oncology, Inc. and Cue Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
CUE
Cue Biopharma, Inc.
$24.16HealthcareDelayed quote: Oct 6, 2026, 11:34 AM EDT
Total return — CHRS vs CUE
growth of $100 · dividends reinvested · last 9yCHRS -87.3% (-20.5%/yr)CUE -93.0% (-25.6%/yr)CHRS compounded faster over this window
CHRS CUE
CHRS vs CUE: by the numbers
- •CUE is the larger company ($176M vs $165M market cap).
- •Both run net losses; CHRS's is the smaller (-257.10% vs -435.83% net margin).
- •CUE grew revenue faster over the past five years (47.08% vs -33.60% CAGR).
Metrics side by side
Valuation
| Metric | CHRS | CUE |
|---|---|---|
| P/S ratio | 3.23 | 4.66 |
| P/B ratio | 2.70 | 75.98 |
Profitability
| Metric | CHRS | CUE |
|---|---|---|
| Gross margin | 63.55% | 99.69% |
| Operating margin | -425.72% | -96.56% |
| Net margin | -257.10% | -435.83% |
| ROE | -215.26% | -7104.24% |
| ROIC | -135.38% | -1039.56% |
Growth (annualized)
| Metric | CHRS | CUE |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | 47.08% |
| Total return CAGR (5Y) | -41.38% | -42.42% |
Frequently asked
- Which has grown faster, CHRS or CUE?
- Over the past five years, CUE grew revenue faster — CHRS at a -33.60% CAGR versus CUE at 47.08%.
- How have CHRS and CUE total returns compared?
- Over the past 5 years, CHRS delivered -41.38% and CUE delivered -42.42% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Coherus Oncology ROECue Biopharma ROECoherus Oncology operating marginCue Biopharma operating marginCoherus Oncology revenue growthCue Biopharma revenue growthCoherus Oncology free cash flowCue Biopharma free cash flow
Coherus Oncology & Cue Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.